
    
      This is a within-subject, controlled open-label study seeking to determine if EPI-589 can
      alter the biochemical signature of PD as assessed by peripheral blood and brain imaging
      biomarkers. Data will also be collected on disease-relevant clinical measures will be
      collected.
    
  